Informazione Regolamentata n. 20279-40-2026	Data/Ora Inizio Diffusione 10 Novembre 2026 15:20:09	Euronext Growth Milan

Societa'	:	VALTECNE
Utenza - referente	:	VALTECNENSS01 - Ottonello Adolfo
Tipologia	:	3.1
Data/Ora Ricezione	:	10 Novembre 2026 15:20:09
Data/Ora Inizio Diffusione	:	10 Novembre 2026 15:20:09
Oggetto	:	THE BOARD OF DIRECTORS OF VALTECNE S.P.A. APPROVED THE CONSOLIDATED REVENUES FOR THE FIRST NINE MONTHS OF 2026

Testo del comunicato

Vedi allegato

Teleborsa: distribution and commercial use strictly prohibited

PRESS RELEASE

THE BOARD OF DIRECTORS OF VALTECNE S.P.A. APPROVED THE CONSOLIDATED REVENUES FOR THE FIRST NINE MONTHS OF 2026

MEDICAL LINE CONFIRMED AS THE GROUP'S CORE BUSINESS, WITH AN INCIDENCE OF OVER 70% ON TOTAL REVENUES

INDUSTRIAL BUSINESS LINE REVENUES GROW BY 7%, CONTRIBUTING TO THE GROUP'S RESULTS

Berbenno di Valtellina (SO), 10 November 2026 – The Board of Directors of **Valtecne S.p.A.** (ISIN IT0005532525, ticker VLT.IM) – a company operating in the high-precision mechanics sector for medical devices and industrial applications – met on today's date and approved the consolidated sales revenues as of 30 September 2026, which have not been audited. Consolidated revenues amounted to € 27.1 million (€ 28.3 million as of 30 September 2025).

Paolo Mainetti, Chief Executive Officer of Valtecne S.p.A., commented: *"The results of the first nine months demonstrate the solidity of our business model and the soundness of our strategic decisions. The Medical sector remains the Group's core business and has seen a slight decline, due solely to the timing of revenue recognition related to stock production contracts. At the same time, the strong performance of the Industrial business line has allowed us to optimally utilize production capacity, benefiting profitability".*

Below is the breakdown of consolidated revenues for the first nine months of 2026 compared with the corresponding period of 2025, by business line.

CONSOLIDATED					
SALES REVENUES (Euro/Thousands)	**30/09/2026**	**% of Total**	**30/09/2025**	**% of Total**	**Change %**
Medical Business Line	19,332	71.4%	21,085	74.4%	-8.3%
Industrial Business Line	7,741	28.6%	7,262	25.6%	6.6%
Total	**27,073**	**100%**	**28,347**	**100%**	**-4.5%**

In the first nine months of 2026, **total consolidated revenues** amounted to **€ 27.1 million**, down from € 28.3 million as of 30 September 2025. Specifically, the **Medical business line** recorded sales revenues of € 19.3 million, down from the first nine months of 2025 (€ 21.1 million), due to the timing of revenue distribution resulting from stock production contracts. However, the medical business line remains the Group's strategic priority, accounting for 71.4% of total revenues. The **Industrial business line** recorded sales revenues of € 7.7

Teleborsa: distribution and commercial use strictly prohibited

million, up 6.6% compared to € 7.3 million in the same period of 2025. The increase reflects the Group's decision to maximize production capacity utilization during the reporting period, resulting in benefits in terms of operating margins.

* * *

This press release is also available on the Company's website https://www.valtecne.com in the "Investors" section and on https://www.emarketstorage.it/.

* * *

***About* Valtecne**

Founded in 1983, Valtecne is a leading company in high-precision mechanics. It manufactures components used in the medical sector – particularly surgical instruments for orthopedics and implantable components – as well as in various industrial sectors such as power transmission, automotive, and energy. As of 31 December 2025, Valtecne reported Production Value of € 37.3 million and Adjusted EBITDA of € 9.7 million, corresponding to an EBITDA margin of 26.0%.

Contacts:

Euronext Growth Advisor – CFO SIM S.p.A.
ecm@cfosim.com
Tel. + 02 30343 1

Corporate Media Relations Office – CDR Communication
Martina Zuccherini martina.zuccherini@cdr-communication.it

Specialist – MIT SIM
trading-desk@mitsim.it
Tel +39 02 305 612 70

Fine Comunicato n.20279-40-2026	Numero di Pagine: 4